IONS (Ionis Pharmaceuticals, Inc.) Stock Financials & Earnings

IONSIonis Pharmaceuticals, Inc.

Mkt Cap$13B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$943M

Net Income (TTM)-$381M

EPS (TTM)-$2.46

Free Cash Flow (TTM)-$320M

Gross Margin98.3%

Op. Margin-40.5%

Net Margin-40.4%

FCF Margin-33.9%

P/S Ratio (TTM)13.4x

P/E Ratio (TTM)—

YoY Rev Growth+33.8%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$131M	$129M	-$114M
Q2 23	$188M	$186M	-$90M
Q3 23	$144M	$142M	-$143M
Q4 23	$325M	$321M	-$6M
Q1 24	$119M	$117M	-$150M
Q2 24	$225M	$221M	-$66M
Q3 24	$134M	$133M	-$149M
Q4 24	$227M	$223M	-$111M
Q1 25	$132M	$130M	-$147M
Q2 25	$452M	$448M	$140M
Q3 25	$157M	$154M	-$160M
Q4 25	$203M	$195M	-$215M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$198M	$46M	—	—
Q2 23	$230M	$46M	$42K	—
Q3 23	$215M	$70M	—	—
Q4 23	$257M	$71M	—	—
Q1 24	$214M	$53M	—	—
Q2 24	$222M	$65M	—	—
Q3 24	$220M	$62M	—	—
Q4 24	$245M	$88M	—	—
Q1 25	$201M	$76M	—	—
Q2 25	$217M	$91M	—	—
Q3 25	$218M	$97M	—	—
Q4 25	$280M	—	—	$130M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$309M	$2.0B	$2.3B
Q2 23	$425M	$2.0B	$2.4B
Q3 23	$352M	$1.9B	$2.2B
Q4 23	$399M	$1.9B	$2.3B
Q1 24	$349M	$1.9B	$2.2B
Q2 24	$294M	$1.8B	$2.1B
Q3 24	$335M	$2.1B	$2.5B
Q4 24	$242M	$2.1B	$2.3B
Q1 25	$264M	$1.9B	$2.1B
Q2 25	$297M	$2.0B	$2.3B
Q3 25	$338M	$1.9B	$2.2B
Q4 25	$372M	$2.3B	$2.7B

Shares Outstanding

Revenue Per Employee

Revenue / Employee